Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0BM7M
|
||||
| Former ID |
DCL000486
|
||||
| Drug Name |
AZD8931
|
||||
| Drug Type |
Small molecular drug
|
||||
| Company |
AstraZeneca
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C23H25ClFN5O3
|
||||
| InChI |
InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)
|
||||
| InChIKey |
DFJSJLGUIXFDJP-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
16590003, 23622332, 42567199, 80594667, 104253512, 124757635, 125164439, 135727457, 135727830, 136367466, 136368073, 136920286, 137166714, 138013466, 138192963, 144115660, 162011769, 162037806, 163642707, 163908019, 165246681, 174006599, 174507796, 174530908, 175449670, 185992959, 198989379, 223366050, 223401932, 223705284, 226558701, 244694478, 249814500, 251962992, 252214940, 252439600, 252451838
|
||||
| Target and Pathway | |||||
| Target(s) | Receptor protein-tyrosine kinase erbB-2 | Target Info | Inhibitor | [550278], [550288] | |
| KEGG Pathway | ErbB signaling pathway | ||||
| Calcium signaling pathway | |||||
| HIF-1 signaling pathway | |||||
| Focal adhesion | |||||
| Adherens junction | |||||
| Pathways in cancer | |||||
| Proteoglycans in cancer | |||||
| MicroRNAs in cancer | |||||
| Pancreatic cancer | |||||
| Endometrial cancer | |||||
| Prostate cancer | |||||
| Bladder cancer | |||||
| Non-small cell lung cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| EGF receptor signaling pathway | |||||
| PathWhiz Pathway | Phosphatidylinositol Phosphate Metabolism | ||||
| WikiPathways | DNA Damage Response (only ATM dependent) | ||||
| ErbB Signaling Pathway | |||||
| EGF/EGFR Signaling Pathway | |||||
| Focal Adhesion | |||||
| Extracellular vesicle-mediated signaling in recipient cells | |||||
| Bladder Cancer | |||||
| Signaling by ERBB2 | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| Signaling Pathways in Glioblastoma | |||||
| Leptin signaling pathway | |||||
| miR-targeted genes in muscle cell - TarBase | |||||
| Semaphorin interactions | |||||
| References | |||||
| Ref 524722 | ClinicalTrials.gov (NCT02117167) Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients. U.S. National Institutes of Health. | ||||
| Ref 542691 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7717). | ||||
| Ref 550278 | Characterization of AZD8931, a potent reversible small molecule inhibitor against epidermal growth factor receptor (EGFR), erythroblastic leukemia viral oncogene homolog 2 (HER2) and 3 (HER3) with a unique and balanced pharmacological profile. J Clin Oncol 27:15s, 2009. | ||||
| Ref 550288 | Clinical pipeline report, company report or official report of AstraZeneca (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.